Continuing parent firm Gilead’s busy deal-making year in immuno-oncology, Kite gets option rights to new targets. Boehringer teams with Israel’s BiomX in IBD research.

Takeda’s collaboration with the private UK biotech includes NASH and other liver disorders. Reliance will take on Amazon in the India pharmacy space with acquisition of Netmeds.

Headquartered in both China and US, the new firm will help partners bring drugs to China and other Asian markets. Novavax licenses COVID-19 vaccine in Japan to Takeda, following previous week’s deal for the vaccine in India.

The company already has more than 20 subsidiaries developing treatments for monogenic diseases and genetically defined cancers, but its deal-making pace has not slowed.